Tag: Orphan Drug

License from Mid-Atlantic BioTherapeutics for IMT504 Broadens Scope of Initial License Beyond Treatment of Symptomatic Rabies Boca Raton, FL, October 7, 2021 – Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”) announced today that the Company has reached […]

Appointment of Independent Director and Chairman of Audit Committee Expands Financial Expertise on Board Boca Raton, FL, July 20, 2021 — Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development stage biomedical company focused on novel therapies […]

Company Appoints Kapil Bharti, Ph.D., and Dimiter Dimitrov, Ph.D. to Scientific and Clinical Advisory Board Boca Raton, FL / iCrowd Newswire/ April 29, 2021 / Curative Biotechnology, Inc.  (OTC: CUBT) a development-stage biomedical company focused on novel therapies for rare diseases, announced today the […]

Boca Raton, FL (Feburary 04, 2021) – Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases today announced it has entered into an Exclusive Patent License Agreement […]

Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases, announced today the Company has signed a definitive agreement with Mid-Atlantic BioTherapeutics, Inc. (MABT) to acquire worldwide rights […]